Literature DB >> 27838307

Plaque Composition in the Proximal Superficial Femoral Artery and Peripheral Artery Disease Events.

Mary M McDermott1, Christopher M Kramer2, Lu Tian3, James Carr4, Jack M Guralnik5, Tamar Polonsky6, Timothy Carroll7, Melina Kibbe8, Michael H Criqui9, Luigi Ferrucci10, Lihui Zhao11, Daniel S Hippe12, John Wilkins13, Dongxiang Xu12, Yihua Liao11, Walter McCarthy14, Chun Yuan12.   

Abstract

OBJECTIVES: The aim of this study was to describe associations of the presence of lipid-rich necrotic core (LRNC) in the proximal superficial femoral artery (SFA) with lower extremity peripheral artery disease (PAD) event rates and systemic cardiovascular event rates.
BACKGROUND: LRNC in the coronary and carotid arteries is associated with adverse outcomes but has not been studied previously in lower extremity arteries.
METHODS: Participants with ankle-brachial index (ABI) values <1.00 were identified from Chicago medical centers and followed annually. Magnetic resonance imaging was used to characterize SFA atherosclerotic plaque at baseline. Medical records for hospitalizations and procedures after baseline were adjudicated for lower extremity revascularization, amputation, and critical limb ischemia and also for new coronary events, ischemic stroke, and mortality.
RESULTS: Of 254 participants with PAD, 62 (24%) had LRNC and 149 (59%) had calcium in the SFA at baseline. Cox regression analyses were adjusted for age, sex, race, comorbidities, baseline ABI, and other confounders. SFA LRNC was associated with an increased incidence of the combined outcome of lower extremity amputation, critical limb ischemia, ABI decline >0.15, and revascularization at 47-month follow-up (hazard ratio: 2.18; 95% confidence interval: 1.27 to 3.75; p = 0.005). The association of SFA LRNC with PAD events was maintained even when this combined outcome excluded lower extremity revascularization (hazard ratio: 2.58; 95% confidence interval: 1.25 to 5.33; p = 0.01). LRNC in the SFA was not associated with all-cause mortality, acute coronary events, or stroke.
CONCLUSIONS: Among patients with PAD, LRNC in the SFA was associated with higher rates of clinical PAD events, and this association was independent of ABI. Further study is needed to determine whether interventions that reduce SFA LRNC prevent PAD events.
Copyright © 2017 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  MRI; femoral artery; lipid rich necrotic core; vascular medicine

Mesh:

Substances:

Year:  2016        PMID: 27838307      PMCID: PMC5701810          DOI: 10.1016/j.jcmg.2016.08.012

Source DB:  PubMed          Journal:  JACC Cardiovasc Imaging        ISSN: 1876-7591


  37 in total

1.  Magnetic resonance imaging of carotid atherosclerotic plaque in clinically suspected acute transient ischemic attack and acute ischemic stroke.

Authors:  Jaywant P Parmar; Walter J Rogers; John P Mugler; Erol Baskurt; Talissa A Altes; Kiran R Nandalur; George J Stukenborg; C Douglas Phillips; Klaus D Hagspiel; Alan H Matsumoto; Michael D Dake; Christopher M Kramer
Journal:  Circulation       Date:  2010-11-01       Impact factor: 29.690

Review 2.  Ultrasound and lipoproteins as predictors of lipid-rich, rupture-prone plaques in the carotid artery.

Authors:  M L Grønholdt
Journal:  Arterioscler Thromb Vasc Biol       Date:  1999-01       Impact factor: 8.311

3.  Lower ankle/brachial index, as calculated by averaging the dorsalis pedis and posterior tibial arterial pressures, and association with leg functioning in peripheral arterial disease.

Authors:  M M McDermott; M H Criqui; K Liu; J M Guralnik; P Greenland; G J Martin; W Pearce
Journal:  J Vasc Surg       Date:  2000-12       Impact factor: 4.268

4.  Evidence of a chronic systemic cause of instability of atherosclerotic plaques.

Authors:  P M Rothwell; R Villagra; R Gibson; R C Donders; C P Warlow
Journal:  Lancet       Date:  2000-01-01       Impact factor: 79.321

5.  Plaque burden, arterial remodeling and plaque vulnerability: determined by systemic factors?

Authors:  A Vink; A H Schoneveld; W Richard; D P de Kleijn; E Falk; C Borst; G Pasterkamp
Journal:  J Am Coll Cardiol       Date:  2001-09       Impact factor: 24.094

6.  Exertional leg pain in patients with and without peripheral arterial disease.

Authors:  Jimmy C Wang; Michael H Criqui; Julie O Denenberg; Mary M McDermott; Beatrice A Golomb; Arnost Fronek
Journal:  Circulation       Date:  2005-11-29       Impact factor: 29.690

7.  Leg symptoms in peripheral arterial disease: associated clinical characteristics and functional impairment.

Authors:  M M McDermott; P Greenland; K Liu; J M Guralnik; M H Criqui; N C Dolan; C Chan; L Celic; W H Pearce; J R Schneider; L Sharma; E Clark; D Gibson; G J Martin
Journal:  JAMA       Date:  2001-10-03       Impact factor: 56.272

8.  Superficial femoral artery plaque, the ankle-brachial index, and leg symptoms in peripheral arterial disease: the walking and leg circulation study (WALCS) III.

Authors:  Mary M McDermott; Kiang Liu; James Carr; Michael H Criqui; Lu Tian; Debiao Li; Luigi Ferrucci; Jack M Guralnik; Christopher M Kramer; Chun Yuan; Melina Kibbe; William H Pearce; Jarett Berry; Walter McCarthy; Yihua Liao; Dongxiang Xu; Jennifer Orozco; Timothy J Carroll
Journal:  Circ Cardiovasc Imaging       Date:  2011-03-24       Impact factor: 7.792

9.  Associations of borderline and low normal ankle-brachial index values with functional decline at 5-year follow-up: the WALCS (Walking and Leg Circulation Study).

Authors:  Mary M McDermott; Jack M Guralnik; Lu Tian; Kiang Liu; Luigi Ferrucci; Yihua Liao; Leena Sharma; Michael H Criqui
Journal:  J Am Coll Cardiol       Date:  2009-03-24       Impact factor: 24.094

10.  Local atherosclerotic plaques are a source of prognostic biomarkers for adverse cardiovascular events.

Authors:  Dominique P V de Kleijn; Frans L Moll; Willem E Hellings; Gonen Ozsarlak-Sozer; Peter de Bruin; Pieter A Doevendans; Aryan Vink; Louise M Catanzariti; Arjan H Schoneveld; Ale Algra; Mat J Daemen; E A Biessen; W de Jager; Huoming Zhang; Jean-Paul de Vries; Erling Falk; Sai K Lim; Peter J van der Spek; Siu Kwan Sze; Gerard Pasterkamp
Journal:  Arterioscler Thromb Vasc Biol       Date:  2009-12-17       Impact factor: 8.311

View more
  5 in total

1.  Femoral artery plaque characteristics, lower extremity collaterals, and mobility loss in peripheral artery disease.

Authors:  Mary M McDermott; Timothy Carroll; James Carr; Chun Yuan; Luigi Ferrucci; Jack M Guralnik; Melina Kibbe; Michael H Criqui; Lu Tian; Tamar Polonsky; Lihui Zhao; Ying Gao; Daniel S Hippe; Dongxiang Xu; Walter McCarthy; Christopher M Kramer
Journal:  Vasc Med       Date:  2017-09-30       Impact factor: 3.239

2.  Stem cell-derived exosomes prevent pyroptosis and repair ischemic muscle injury through a novel exosome/circHIPK3/ FOXO3a pathway.

Authors:  Bing Yan; Yu Zhang; Chun Liang; Bin Liu; Fengzhi Ding; Yanli Wang; Bao Zhu; Ranzun Zhao; Xi-Yong Yu; Yangxin Li
Journal:  Theranostics       Date:  2020-05-18       Impact factor: 11.556

3.  Ultra-high resolution, 3-dimensional magnetic resonance imaging of the atherosclerotic vessel wall at clinical 7T.

Authors:  Martin J Willemink; Bram F Coolen; Hadrien Dyvorne; Philip M Robson; Ilda Bander; Seigo Ishino; Alison Pruzan; Arthi Sridhar; Bei Zhang; Priti Balchandani; Venkatesh Mani; Gustav J Strijkers; Aart J Nederveen; Tim Leiner; Zahi A Fayad; Willem J M Mulder; Claudia Calcagno
Journal:  PLoS One       Date:  2020-12-14       Impact factor: 3.240

4.  The risk factors for calcification vary among the different sections of the lower extremity artery in patients with symptomatic peripheral arterial disease.

Authors:  Hankun Yan; Zhihui Chang; Zhaoyu Liu
Journal:  BMC Cardiovasc Disord       Date:  2020-07-11       Impact factor: 2.298

5.  Transatlantic Lipid Guideline Divergence: Same Data But Different Interpretations.

Authors:  Carl E Orringer; Lale Tokgozoglu; Kevin C Maki; Kausik K Ray; Joseph J Saseen; Alberico L Catapano
Journal:  J Am Heart Assoc       Date:  2020-10-23       Impact factor: 5.501

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.